INCB-086550 clinical trials
Also written INCB086550.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses INCB-086550 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- INCB086550
- 4
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses INCB-086550 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550TerminatedPhase 1Incyte Biosciences Japan GKNCT04674748Written as INCB086550How we know
- A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550CompletedPhase 1Incyte CorporationNCT05101369Written as INCB086550How we know
- A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid TumorsCompletedPhase 1Incyte CorporationNCT03762447Written as INCB086550How we know
- Study of INCB086550 in Select Solid TumorsTerminatedPhase 2Incyte CorporationNCT04629339Written as INCB086550How we know
Codes
What other systems call INCB-086550 · ClinicalTrials.gg INT017999
- UNII (FDA) T8B91S15VFINCB-086550One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T8B91S15VF | INCB-086550 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.